Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Company is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient's immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis. ...
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 12 July 2025
2018-02-11 07:30:00 Sunday ET
President Trump unveils his ambitious $1.5 trillion public infrastructure plan. Trump proposes offering $100 billion in federal incentives to encourage stat
2025-03-03 04:11:06 Monday ET
Is higher stock market concentration good or bad for Corporate America? In recent years, S&P 500 stock market returns exhibit spectacular concentrati
2018-01-09 08:33:00 Tuesday ET
BlackRock CEO Larry Fink emphasizes his key conviction that public corporations should make a positive contribution to society apart from boosting the botto
2017-03-27 06:33:00 Monday ET
Goldman Sachs chief economist Jan Hatzius says the Federal Reserve's QE exit strategy makes sense ahead of Fed Chair Janet Yellen's stepdown in 2018
2017-11-03 06:41:00 Friday ET
Broadcom, a one-time division of Hewlett-Packard and now a semiconductor maker whose chips help power iPhone X, has announced its strategic plans to move it
2019-08-18 11:33:00 Sunday ET
House Judiciary Committee summons senior executive reps of the tech titans to assess online platforms and their market power. These companies are Facebook,